Perettie will succeed Troy Cox. Perettie brings more than two decades of scientific and commercial experience with global biopharmaceutical organisations, most recently having served as a senior vice president in global oncology product strategy for Roche's Oncology unit.
She joins Foundation Medicine from Roche, where she's led one of the largest global oncology portfolios. Perettie has led several successful product launches in the US and abroad for Roche and Genentech across the oncology portfolio, including in breast cancer and hematology.
Perettie began her tenure at Genentech as a program team leader for bevacizumab, focused on lung cancer, breast cancer, gastrouterine cancer and melanoma.
She has held roles of increasing responsibility at Genentech since joining in 2004, including vice president of global regulatory operations and regional head of Europe, Middle East and Africa operations and global development.
Perettie took a hiatus from Genentech in 2012 to join Sarah Cannon Research Institute as president, Global Development Innovations.
There, she was responsible for leading and growing SCRI's contract research organization business globally, driving the execution of critical oncology clinical trials during her tenure.
Before joining Genentech, Perettie lead portfolio management at IVAX Pharmaceuticals and was the director of global program management at Élan Corp.
She started her career as a senior research associate at Johns Hopkins University, before taking on a research scientist associate director role at Chiron Corp.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review